-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Prelude Therapeutics Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
- Prelude Therapeutics Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$34.7M, a 14.2% decline year-over-year.
- Prelude Therapeutics Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$130M, a 11.2% decline year-over-year.
- Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$122M, a 5.54% decline from 2022.
- Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$115M, a 3.35% decline from 2021.
- Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$112M, a 96.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)